Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $39,498.20 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 1,780 shares of the stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $22.19, for a total transaction of $39,498.20. Following the transaction, the insider directly owned 83,058 shares in the company, valued at $1,843,057.02. The trade was a 2.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS opened at $19.94 on Friday. The stock has a market capitalization of $2.52 billion, a P/E ratio of 64.32 and a beta of 0.31. The business has a 50-day moving average of $22.89 and a two-hundred day moving average of $23.45. Apellis Pharmaceuticals, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $31.17. The company has a debt-to-equity ratio of 0.90, a current ratio of 3.54 and a quick ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a return on equity of 18.94% and a net margin of 4.43%.The business had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same period last year, the business earned ($0.46) EPS. The firm’s revenue was up 133.0% compared to the same quarter last year. On average, equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on APLS. Mizuho lowered their target price on shares of Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Needham & Company LLC dropped their price objective on Apellis Pharmaceuticals from $29.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. Weiss Ratings restated a “sell (d)” rating on shares of Apellis Pharmaceuticals in a research note on Monday, December 29th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $19.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, January 12th. Finally, TD Cowen cut their price target on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Eleven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $33.65.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC raised its holdings in Apellis Pharmaceuticals by 80.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after acquiring an additional 855 shares in the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company’s stock worth $46,000 after purchasing an additional 1,373 shares in the last quarter. Allworth Financial LP increased its position in shares of Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company’s stock valued at $50,000 after purchasing an additional 857 shares during the period. Osaic Holdings Inc. raised its stake in shares of Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock valued at $47,000 after purchasing an additional 1,570 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Apellis Pharmaceuticals in the third quarter valued at $64,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Key Apellis Pharmaceuticals News

Here are the key news stories impacting Apellis Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo reiterated a Buy on Apellis, signaling continued confidence in the company’s longer‑term commercial execution and pipeline upside — a supportive voice for holders focused beyond near‑term sales. Read More.
• Positive Sentiment: Stifel Nicolaus issued a Buy on APLS (or reiterated constructive coverage), adding a second favorable analyst view that could help stabilize valuation if execution improves. Read More.
• Neutral Sentiment: Analysts remain mixed on Apellis: some see upside from Syfovre rollout and nephrology expansion while others emphasize near‑term sales risk and valuation — expect continued divergent research notes and volatile price reactions to company updates. Read More.
• Negative Sentiment: Apellis reported preliminary Q4 U.S. net product revenue of $190M and flagged weaker Syfovre sales with mixed Empaveli uptake — the main near‑term driver cited for a recent sharp weekly decline in the stock. Read More.
• Negative Sentiment: Major research houses (Cantor Fitzgerald, Needham) issued more pessimistic forecasts or lowered expectations, increasing downward pressure by reducing modeled revenues and price targets. Read More. Read More.
• Negative Sentiment: Significant insider selling on Jan. 13: multiple senior execs (CEO Cedric Francois, CFO Timothy Sullivan, General Counsel David Watson and others) sold shares at ~ $22.19 — filings show they still retain large stakes but the volume of disposals can be perceived negatively by the market. Read More.
• Negative Sentiment: Options flow indicated a large spike in put buying (reported >500% increase in put volume), reflecting elevated hedging and bearish positioning that can amplify short‑term volatility and downside pressure. Source: options flow reports

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.